| __timestamp | Halozyme Therapeutics, Inc. | Mesoblast Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 35942000 | 54170000 |
| Thursday, January 1, 2015 | 40028000 | 65378000 |
| Friday, January 1, 2016 | 45853000 | 52263000 |
| Sunday, January 1, 2017 | 53816000 | 35072000 |
| Monday, January 1, 2018 | 60804000 | 27415000 |
| Tuesday, January 1, 2019 | 77252000 | 36983000 |
| Wednesday, January 1, 2020 | 45736000 | 50918000 |
| Friday, January 1, 2021 | 50323000 | 63586000 |
| Saturday, January 1, 2022 | 143526000 | 57967000 |
| Sunday, January 1, 2023 | 149182000 | 53107000 |
| Monday, January 1, 2024 | 154335000 | 23626000 |
Unleashing insights
In the competitive landscape of biotechnology, understanding financial trends is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Halozyme Therapeutics, Inc. and Mesoblast Limited from 2014 to 2023. Over this period, Halozyme's SG&A expenses surged by approximately 315%, peaking in 2023, while Mesoblast's expenses fluctuated, showing a 56% decrease from their 2015 high.
Halozyme Therapeutics: The company experienced a significant increase in SG&A expenses, particularly between 2021 and 2023, where expenses nearly tripled. This could indicate strategic investments in marketing and administration to support growth.
Mesoblast Limited: Despite a peak in 2015, Mesoblast's expenses have generally declined, suggesting a focus on cost efficiency or a shift in strategic priorities.
These trends highlight differing strategic approaches in managing operational costs within the biotech sector.
Comparing SG&A Expenses: AstraZeneca PLC vs Halozyme Therapeutics, Inc. Trends and Insights
Breaking Down SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Halozyme Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Incyte Corporation or Halozyme Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Summit Therapeutics Inc. and Halozyme Therapeutics, Inc.
Comparing SG&A Expenses: Walgreens Boots Alliance, Inc. vs Halozyme Therapeutics, Inc. Trends and Insights
Halozyme Therapeutics, Inc. or Amneal Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Halozyme Therapeutics, Inc. and Mesoblast Limited: A Comprehensive Revenue Analysis
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs Mesoblast Limited
Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs Mesoblast Limited
Cost Management Insights: SG&A Expenses for Protagonist Therapeutics, Inc. and Mesoblast Limited
SG&A Efficiency Analysis: Comparing Mesoblast Limited and Agios Pharmaceuticals, Inc.
Mesoblast Limited or Xencor, Inc.: Who Manages SG&A Costs Better?